In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Guimarães, Fernando S F ^a   Andrade, Lucas F ^a   Martins, Sharon T ^a   Abud, Ana P R ^a   Sene, Reginaldo V ^a   Wanderer, Carla ^a   Tiscornia, Inés ^b   Bollati Fogolín, Mariela ^b   Buchi, Dorly F ^a   Trindade, Edvaldo S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCAREA CARBONICA DERIVATIVE COMPLEX; M 8; PERLECAN; UNCLASSIFIED DRUG; MATERIA MEDICA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INVASION; CELL ADHESION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL STRAIN HT29; COLORECTAL TUMOR; EXPERIMENTAL MELANOMA; IMMUNOPHENOTYPING; LUNG TUMOR; METASTASIS; PATHOLOGY;

ANIMALS; BONE MARROW CELLS; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; MALE; MATERIA MEDICA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C;

EID: 77952255865     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-113     Document Type: Article

References (39)

1. Rigel DS, Carucci JA. Malignant melanoma: Prevention, early detection, and treatment in the 21st Century. CA-Cancer J Clin 2000, 50:215-36. 10.3322/canjclin.50.4.215, 10986965.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005, 365:687-701.
3. Smalley KS, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer 2009, 124(6):1245-50. 10.1002/ijc.24129, 19089923.
4. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007, 121:2562-2566. 10.1002/ijc.22951, 17680564.
5. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996, 56:172-181.
6. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005, 96:897-905. 10.1002/jcb.20602, 16149080.
7. Fjeldstad K, Kolset SO. Decreasing the metastatic potential in cancers - targeting the heparan sulfate proteoglycans. Curr Drug Tar 2005, 6:665-82.
8. Bergman PJ. Cancer immunotherapy. Top Companion Anim Med 2009, 24:130-136. 10.1053/j.tcam.2009.06.001, 19732731.
9. Piemonte MR, Buchi DF. Analysis of IL-2, IFN-gamma and TNF-alpha production, alpha5 beta1 integrins and actin filaments distribution in peritoneal mouse macrophages treated with homeopathic medicament. J Submicr Cytol Pathol 2002, 34(3):255-263.
10. Oliveira CC, Oliveira SM, Godoy LM, Gabardo J, Buchi DF. Canova, a Brazilian medical formulation, alters oxidative metabolism of mice macrophages. J Infection 2006, 52:420-32.
11. Oliveira CC, Oliveira SM, Goes VM, Probst CM, Krieger MA, Buchi DF. Gene expression profiling of macrophages following mice treatment with an immunomodulator medication. J Cell Biochem 2008, 104:1364-77. 10.1002/jcb.21713, 18286468.
12. Seligmann IC, Lima PD, Cardoso PC, Khayat AS, Bahia MO, Buchi DF, Cabral IR, Burbano RR. The anticancer homeopathic composite "Canova Method" is not genotoxic for human lymphocytes in vitro. Genet Mol Res 2003, 2:223-228.
13. Sato DY, Wal R, Oliveira CC, Cattaneo RI, Malvezzi M, Gabardo J, Buchi DF. Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a Brazilian homeopathic medication. Homeopathy 2005, 94(1):26-32. 10.1016/j.homp.2004.10.003, 15751331.
14. Abud AP, Cesar B, Cavazzani LF, Oliveira CC, Gabardo J, Buchi DF. Activation of bone marrow cells treated with Canova in vitro. Cell Biol Int 2006, 30(10):808-816. 10.1016/j.cellbi.2006.06.011, 16884931.
15. Cesar B, Abud APR, Oliveira CC, Cardoso F, Gremski W, Gabardo J, Buchi DF. Activation of mononuclear bone marrow cells treated in vitro with a complex homeopathic medication. Micron 2008, 39(4):461-470. 10.1016/j.micron.2007.02.005, 17379529.
16. Cesar B, Abud APR, Oliveira CC, Cardoso F, Bernardi RP, Guimaraes FSF, Gabardo J, Buchi DF. Treatment with at homeopathic complex medication modulates mononuclear bone marrow cell differentiation. Evid Based Complement Alternat Med
17. Guimaraes FSF, Abud AP, Oliveira SM, Oliveira CC, César B, Donatti L, Gabardo J, Trindade ES, Buchi DF. Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication. BMC Cancer 2009, 9:293. 10.1186/1471-2407-9-293, 2749867, 19698142.
18. Bollati-Fogolín M, Müller W. Virus free, cell-based assay for the quantification of murine type I interferons. J Immunol Methods 2005, 306:169-175. 10.1016/j.jim.2005.08.005, 16209875.
19. Zhao W, Liu H, Xu S, Entschladen F, Niggemann B, Zänker KS, Han R. Migration and metalloproteinases determine the invasive potential of mouse melanoma cells, but not melanin and telomerase. Cancer Lett 2001, 162:49-55. 10.1016/S0304-3835(00)00656-X, 11121862.
20. Dua P, Gude RP. Antiproliferative and antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells. Cancer Chemother Pharmacol 2006, 58:195-202. 10.1007/s00280-005-0155-8, 16331498.
21. McConville JT, Willians RO, Carvalho TC, Iberg AN, Johnston KP, Talbert RL, Burgess D, Peters JI. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Develop Ind Pharm 2005, 31:35-42.
22. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007, 60:596-599. 10.1136/jcp.2005.032144, 16522748.
23. Guimaraes FSF, Oliveira SM, Oliveira CC, Donatti L, Buchi DF. A shorter fixation protocol for transmission electron microscopy: An alternative to spend less time. Ultrastr Pathol 2009, 33(4):169-74.
24. Milazzo S, Russell N, Ernst E. Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006, 42:282-9. 10.1016/j.ejca.2005.09.025, 16376071.
25. Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee J, Gatto N, Ambs A. The use of complementary and alternative medicine among california adults with and without cancer. Evid Based Complement Alternat Med 2005, 2(4):557-565. 10.1093/ecam/neh138, 1297511, 16322814.
26. Cooper EL. The Immune System and Complementary and Alternative Medicine. Evid Based Complement Alternat Med 2007, 4(S1):5-8. 10.1093/ecam/nem093, 2206233, 18227923.
27. Pascual-Carpe F, Vicente-Ortega V, Campos-Aranda M, Yañez-Gascón J. In vivo treatment of melanoma (B16F10) with a homeopathic agent and with a cytokine (IFN-α). Oncol Res 2006, 16(5):211-216.
28. Es S, Kuttan G, Kc P, Kuttan R. Effect of homeopathic medicines on transplanted tumors in mice. Asian Pac J Cancer Prev 2007, 8(3):390-4.
29. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy. Clin Cancer Res 2004, 10:6606-11. 10.1158/1078-0432.CCR-04-0182, 15475450.
30. Tucci MG, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, Giacchetti A, Ricotti G, Biagini G. Involvement of E-cadherin, b-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Brit J Dermatol 2007, 157:1212-16.
31. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62. 10.1186/1479-5876-6-62, 2605741, 18954464.
32. Pikarsky E, Ben-Neriah Y. NF-κB inhibition: A double-edged sword in cancer?. Eur J Cancer 2006, 42(6):779-84. 10.1016/j.ejca.2006.01.011, 16530406.
33. Rivera J, Tessarollo L. Genetic Background and the Dilemma of Translating Mouse Studies to Humans. Immunity 2008, 28(1):1-4. 10.1016/j.immuni.2007.12.008, 18199409.
34. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocols in Immunology 2001, Chapter 20(Unit 20.1). Wiley-Liss. New York, 2763508, 18432774.
35. Lotfi R, Schrezenmeier H, Lotze MT. Immunotherapy for cancer: promoting innate immunity. Front Biosci 2009, 14:818-32. 10.2741/3280, 19273102.
36. Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003, 51(11):1393-1410.
37. Jiang X, Multhaupt H, Chan E, Schaefer L, Schaefer RM, Couchman JR. Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 2004, 52(12):1575-90. 10.1369/jhc.4A6353.2004, 15557212.
38. Olsen BR. Life without perlecan has its problems. J Cell Biochem 1999, 147(5):909-12.
39. Smith CS, Gulobovskaya VM, Peck E, Xu LH, Monia BP, Yang X, Cance WG. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005, 15(5):357-62. 10.1097/00008390-200510000-00003, 16179862.